Business Description
Q-linea AB
ISIN : SE0025420714
Total Employee Number:
73Compare
Compare
Traded in other countries / regions
QLINEA.Sweden3F80.GermanyQLINEs.UK IPO Date
2018-12-07Description
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -3.57 | |||||
Beneish M-Score | 16.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69.4 | |||||
3-Year EBITDA Growth Rate | 72.3 | |||||
3-Year EPS without NRI Growth Rate | 71.5 | |||||
3-Year FCF Growth Rate | 72.4 | |||||
3-Year Book Growth Rate | -71.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 196.12 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.24 | |||||
9-Day RSI | 42.05 | |||||
14-Day RSI | 43.27 | |||||
3-1 Month Momentum % | -17.77 | |||||
6-1 Month Momentum % | -36.82 | |||||
12-1 Month Momentum % | -67.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 117.99 | |||||
Quick Ratio | 106.15 | |||||
Cash Ratio | 83.23 | |||||
Days Inventory | 1420.25 | |||||
Days Sales Outstanding | 137.13 | |||||
Days Payable | 256.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -341 | |||||
Shareholder Yield % | -76.74 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 26.31 | |||||
Operating Margin % | -1581.1 | |||||
Net Margin % | -1548.03 | |||||
EBITDA Margin % | -1344.14 | |||||
FCF Margin % | -1445.51 | |||||
OCF Margin % | -1389.89 | |||||
ROE % | -67.28 | |||||
ROA % | -55.52 | |||||
ROIC % | -138.98 | |||||
3-Year ROIIC % | -309.44 | |||||
ROC (Joel Greenblatt) % | -239.09 | |||||
ROCE % | -60.27 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 18.08 | |||||
PB Ratio | 1.15 | |||||
Price-to-Tangible-Book | 1.22 | |||||
EV-to-EBIT | -0.94 | |||||
EV-to-EBITDA | -1.05 | |||||
EV-to-Revenue | 14.15 | |||||
EV-to-FCF | -1.01 | |||||
Price-to-GF-Value | 0.85 | |||||
| Price-to-Net-Current-Asset-Value | 1.4 | |||||
| Price-to-Net-Cash | 2.14 | |||||
Earnings Yield (Greenblatt) % | -105.89 | |||||
FCF Yield % | -45.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Q-linea AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 9.859 | ||
| EPS (TTM) (kr) | -13.196 | ||
| Beta | 2.7034 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.53 | ||
| Volatility % | 48.24 | ||
| 14-Day RSI | 43.27 | ||
| 14-Day ATR (kr) | 0.867024 | ||
| 20-Day SMA (kr) | 17.0875 | ||
| 12-1 Month Momentum % | -67.29 | ||
| 52-Week Range (kr) | 14.55 - 59.757925 | ||
| Shares Outstanding (Mil) | 18.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Q-linea AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Q-linea AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 | In 100 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 100 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-10 01:00 | 16.10 (-9.55%) | ||
| Second quarter earnings results for 2026 | 2026-07-10 | 16.10 (-9.55%) | ||
| General meeting for 2026 | 2026-05-27 15:00 | 17.85 (-1.92%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 13:00 | 18.05 (-5.00%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 18.05 (-5.00%) | ||
| Annual report for 2025 | 2026-04-24 | 20.60 (-2.83%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-04 13:00 | 25.83 (-7.72%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-04 | 25.83 (-7.72%) |
Show
Entries
Q-linea AB Frequently Asked Questions
What is Q-linea AB(OSTO:QLINEA)'s stock price today?
The current price of OSTO:QLINEA is kr16.60. The 52 week high of OSTO:QLINEA is kr59.76 and 52 week low is kr14.55.
When is next earnings date of Q-linea AB(OSTO:QLINEA)?
The next earnings date of Q-linea AB(OSTO:QLINEA) is 2026-10-30.
Does Q-linea AB(OSTO:QLINEA) pay dividends? If so, how much?
Q-linea AB(OSTO:QLINEA) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Webinar Friday June 5th: How Can ASTar Improve Infection Diagnostics | 2020-05-25 | ||
| Q-linea Signs Global Partnership With Thermo Fisher Scientific for Commercialization of ASTar | 2020-02-12 |
Articles on Q-linea AB
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers